Sanofi (NASDAQ:SNY) Stock Holdings Lessened by Trust Investment Advisors

Trust Investment Advisors lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 5.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 25,698 shares of the company’s stock after selling 1,502 shares during the quarter. Trust Investment Advisors’ holdings in Sanofi were worth $1,278,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cardinal Capital Management increased its holdings in shares of Sanofi by 0.3% in the 4th quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock worth $2,927,000 after acquiring an additional 201 shares during the period. Daiwa Securities Group Inc. increased its stake in shares of Sanofi by 3.4% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock valued at $325,000 after purchasing an additional 216 shares during the period. Sage Rhino Capital LLC raised its holdings in shares of Sanofi by 2.8% during the third quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock valued at $468,000 after buying an additional 240 shares during the last quarter. Gallacher Capital Management LLC boosted its position in shares of Sanofi by 4.5% during the third quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock worth $307,000 after buying an additional 245 shares during the period. Finally, Captrust Financial Advisors grew its holdings in Sanofi by 0.9% in the 3rd quarter. Captrust Financial Advisors now owns 26,191 shares of the company’s stock worth $996,000 after buying an additional 246 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley began coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. Finally, TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $55.00.

Sanofi Price Performance

NASDAQ SNY traded down $0.72 on Thursday, reaching $45.39. 4,359,459 shares of the stock traded hands, compared to its average volume of 1,897,695. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The company has a market cap of $114.82 billion, a price-to-earnings ratio of 19.25, a P/E/G ratio of 1.71 and a beta of 0.61. The firm’s fifty day simple moving average is $47.55 and its 200 day simple moving average is $48.69. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 12.56% and a return on equity of 27.47%. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. As a group, research analysts predict that Sanofi will post 4.16 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a dividend yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.